Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 462,178
  • Shares Outstanding, K 82,238
  • Annual Sales, $ 78,120 K
  • Annual Income, $ -153,220 K
  • 60-Month Beta 2.09
  • Price/Sales 6.20
  • Price/Cash Flow N/A
  • Price/Book 1.65
Trade EDIT with:

Options Overview Details

View History
  • Implied Volatility 96.99% ( +25.72%)
  • Historical Volatility 67.77%
  • IV Percentile 92%
  • IV Rank 49.07%
  • IV High 161.87% on 04/29/24
  • IV Low 34.46% on 06/28/23
  • Put/Call Vol Ratio 0.17
  • Today's Volume 422
  • Volume Avg (30-Day) 1,291
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 27,935
  • Open Int (30-Day) 33,292

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.69
  • Number of Estimates 10
  • High Estimate -0.46
  • Low Estimate -0.84
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -23.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.91 +12.42%
on 05/08/24
6.69 -17.49%
on 05/15/24
+0.03 (+0.55%)
since 04/19/24
3-Month
4.91 +12.42%
on 05/08/24
11.58 -52.33%
on 02/28/24
-2.43 (-30.57%)
since 02/20/24
52-Week
4.91 +12.42%
on 05/08/24
11.91 -53.65%
on 06/14/23
-3.80 (-40.77%)
since 05/19/23

Most Recent Stories

More News
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?

The company has great potential if and when it enters the commercial stage.

C : 63.16 (-1.42%)
EDIT : 5.52 (-1.78%)
Editas: Q1 Earnings Snapshot

Editas: Q1 Earnings Snapshot

EDIT : 5.52 (-1.78%)
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.

The company now has a chance to get its lead program out the door a bit sooner.

C : 63.16 (-1.42%)
EDIT : 5.52 (-1.78%)
1 Beaten-Down Stock With 55% Upside, According to Wall Street

The biotech has bounced back some in the past year.

EDIT : 5.52 (-1.78%)
Why Editas Medicine Stock Soared as Much as 42% Higher This Week

The clinical-stage genome editing company dropped a couple of important announcements for shareholders.

VRTX : 445.87 (+0.15%)
C : 63.16 (-1.42%)
EDIT : 5.52 (-1.78%)
Editas: Q4 Earnings Snapshot

Editas: Q4 Earnings Snapshot

EDIT : 5.52 (-1.78%)
2 Under-the-Radar Stocks With Incredible Upside Potential

It's also important to consider their downsides.

EDIT : 5.52 (-1.78%)
RXRX : 9.78 (+3.82%)
Could Editas Medicine Become the Next CRISPR Therapeutics?

The similarities between the pair are striking, but it might not be enough.

EDIT : 5.52 (-1.78%)
CRSP : 55.47 (-1.33%)
Down 88%, Could Editas Medicine Be a Good Investment Now?

The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.

VRTX : 445.87 (+0.15%)
CRSP : 55.47 (-1.33%)
EDIT : 5.52 (-1.78%)
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics

These two are at very different stages of the clinical trials process.

EDIT : 5.52 (-1.78%)
NTLA : 25.89 (-1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target...

See More

Key Turning Points

3rd Resistance Point 5.90
2nd Resistance Point 5.81
1st Resistance Point 5.66
Last Price 5.52
1st Support Level 5.43
2nd Support Level 5.34
3rd Support Level 5.20

See More

52-Week High 11.91
Fibonacci 61.8% 9.24
Fibonacci 50% 8.41
Fibonacci 38.2% 7.58
Last Price 5.52
52-Week Low 4.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar